Mid
L
LLYAI Stock Diagnostic Report
Lilly Foundayo is predicted to cut diabetes risk by 57% in late-stage study
An analysis showing that Eli Lilly's obesity drug Zepbound can reduce the risk of type 2 diabetes by 57% in a late-stage clinical trial is positive.
View Source Article ↗AI CATALYST SCORE78 / 100Score computed by Sentinel V12
REFERENCE PRICE$1157.08Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
The detailed analysis of the ATTAIN-1 clinical trial for the oral obesity treatment Foundayo opens up expansion potential into the future diabetes treatment market, providing a solid financial foundation for long-term sales growth.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Additional analysis results from the ATTAIN-1 Phase 3 trial were announced, showing that the Foundayo 17.2 mg treatment group reduced the risk of developing type 2 diabetes by 57% compared to the control group.